octreotide + somatostatin + temozolomide

This is a combination regimen consisting of octreotide, somatostatin, and temozolomide. Octreotide is a synthetic long-acting analogue of the natural hormone somatostatin, which inhibits the secretion of several other hormones and growth factors. Somatostatin itself is an endogenous peptide hormone with similar inhibitory effects on endocrine and exocrine secretion. Temozolomide is an oral alkylating agent that induces DNA damage by methylation, leading to tumor cell death. This combination targets neuroendocrine tumors (NETs), leveraging the antiproliferative and symptom-controlling effects of somatostatin analogues (octreotide/somatostatin) alongside the cytotoxic action of temozolomide. The regimen aims to control hormonal symptoms, slow tumor progression in well-differentiated NETs expressing somatostatin receptors, and induce direct cytotoxicity via DNA alkylation[1][2][3][8].